Cargando…
Mucin architecture behind the immune response: design, evaluation and conformational analysis of an antitumor vaccine derived from an unnatural MUC1 fragment
A tripartite cancer vaccine candidate, containing a quaternary amino acid (α-methylserine) in the most immunogenic domain of MUC1, has been synthesized and examined for antigenic properties in transgenic mice. The vaccine which is glycosylated with GalNAc at the unnatural amino acid, was capable of...
Autores principales: | Martínez-Sáez, Nuria, Supekar, Nitin T., Wolfert, Margreet A., Bermejo, Iris A., Hurtado-Guerrero, Ramón, Asensio, Juan L., Jiménez-Barbero, Jesús, Busto, Jesús H., Avenoza, Alberto, Boons, Geert-Jan, Peregrina, Jesús M., Corzana, Francisco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Royal Society of Chemistry
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977504/ https://www.ncbi.nlm.nih.gov/pubmed/29910919 http://dx.doi.org/10.1039/c5sc04039f |
Ejemplares similares
-
Towards Enantiomerically
Pure Unnatural α-Amino
Acids via Photoredox Catalytic 1,4-Additions to a Chiral Dehydroalanine
por: Oroz, Paula, et al.
Publicado: (2022) -
Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an anti-MUC1 Antibody**
por: Martínez-Sáez, Nuria, et al.
Publicado: (2015) -
Synthesis, conformational analysis and in vivo assays of an anti-cancer vaccine that features an unnatural antigen based on an sp(2)-iminosugar fragment
por: Bermejo, Iris A., et al.
Publicado: (2020) -
MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice
por: Lakshminarayanan, Vani, et al.
Publicado: (2016) -
Synthesis of β(2,2)-Amino Acids by
Stereoselective Alkylation of Isoserine Derivatives Followed by Nucleophilic
Ring Opening of Quaternary Sulfamidates
por: Tovillas, Pablo, et al.
Publicado: (2022)